NovelStem Announces New Research Collaborations for Stem-Cell Technology Platform in Cancer Immunotherapy and COVID-19 Resistance

Press Release – April 21, 2020

Boca Raton, FL & Jerusalem, Israel – NovelStem International Corp. (OTC Pink: NSTM), a biotechnology company focused on its stem cell-based technology platform, developed by Israel-based affiliate, NewStem Ltd., announced two new collaborations to apply NewStem’s technology platform, one to research a potential cancer immunotherapy drug and another to research genes responsible for COVID-19. NovelStem also announced the identification and completion of analysis of resistance to a dozen standard-of-care anti-cancer treatments.